Reach Us +1-504-608-2390
Anti-m?llerian Hormone Deficiency In Females With Inherited Bone Marrow Failure Syndromes | 19636
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Anti-m?llerian hormone deficiency in females with inherited bone marrow failure syndromes

3rd International Conference and Exhibition on Clinical & Cellular Immunology

Martha M Sklavos, Neelam Giri, Pamela Stratton, Sharon Savage, Blanche P Alter and Ligia A Pinto

ScientificTracks Abstracts: J Clin Cell Immunol

DOI: 10.4172/2155-9899.S1.017

Fanconi anemia (FA), dyskeratosiscongenita (DC), and Diamond-Blackfan anemia (DBA) are rare inherited bone marrow failure syndromes (IBMFS) characterized by birth defects, bone marrow failure, and increased frequency of malignancy. Females with FA are known to have a high incidence of infertility which may be associated with primary ovarian insufficiency (POI), while infertility in DC and DBA has not been reported. Anti-M?llerian hormone (AMH) is a marker of ovarian reserve and the decline of AMH is correlated with the loss of fertility as AMH decreases to undetectable levels five to ten years prior to menopause. In this study, we examined whether serum levels of AMH could serve as a menstrual cycle-independent marker for the diagnosis of POI in patients with IBMFS. Serum AMH levels were measured in female participants in the National Cancer Institute?s IBMFS cohort in 22 FA patients (median age 15 years, range 7-37), 20 unaffected FA relatives (age 33.5, range 3-40), 15 patients with DC (age 17, range 4-32), 18 unaffected DC relatives (age 22.5, range 2-40), 12 patients with DBA (age 15.5, range 1-30), 13 unaffected DBA relatives (age 11, range 1-34), and 21 unrelated healthy females (age 27, range 12-40). FA females had very low or undetectable AMH levels (median 0.05 ng/ml, range 0-2.32ng/ml) compared with both unaffected FA relatives (2.10 ng/ml, range 0.04-4.73ng/ml, p<0.0001) and unrelated healthy females (1.92ng/ml, range 0.31-6.64 ng/ml, p<0.0001). All five females with FA over the age of 25 had undetectable AMH levels and were diagnosed with POI. Six of seven FA patients over the age of 20 developed cancer (median age 27; three prevalent, three incident) while all unaffected female relatives and unrelated controls were cancer-free. Females with DC had AMH levels that were significantly lower (0.55 ng/ ml, range 0.01-4.82 ng/ml) than their unaffected relatives (2.33 ng/ml,range0.44-10.03 ng/ml, p=0.001) and unrelated healthy controls (p=0.001) while AMH levels of females with DBA (0.90 ng/ml, range 0-10.20) did not significantly differ from their unaffected relatives (1.71 ng/ml, range: 0.56-5.10 ng/ml, p=0.21) or unrelated healthy controls (p=0.14). One patient with DC reported fertility issues, two patients with DBA were diagnosed with POI, and all three had AMH levels under 1ng/ml. Only one patient with DC had prevalent cancer while DBA patients and all relatives of patients with IBMFS were cancer-free. This study is the first to demonstrate AMH deficiency in females with IBMFS and to suggest that measurement of AMH is useful for the early diagnosis of POI in IBMFS. Our data suggest that AMH may be lower in FA than in DC and DBA. Prior studies indicate that the rates of cancer are highest in FA, followed by DC, and lowest in DBA. Further research is warranted to determine whether there is an association between AMH deficiency and increased cancer risk in IBMFS or within the general (unaffected) population.
Martha Sklavos earned her undergraduate degree from Johns Hopkins University andher PhD in Immunology from the University Of Pittsburgh School Of Medicine. Currently, Martha is a post-doctoral fellow at the HPV Immunology Laboratory at the Frederick National Laboratory for Cancer Research where she was awarded a grant from the National Cancer Institute to investigate a novel biomarker for cervical cancer risk. She is now leading several studies to define the role of this novel biomarker in additional cancer types. Martha enjoys conceptualizing ideas and driving projects forward and hopes to fill a similar role in the pharmaceutical industry upon completion of her post-doctoral training.